Progress in dupilumab for type 2 inflammatory skin disorders
The prevalence of skin disorders in China is as high as 40％～70％,with the incidence rate of type 2 inflammatory skin disease exceeding 10％.Traditional treatment options include glucocorticoids combined with antihistamines or immunosuppressants,which may have drawbacks such as poor disease control and various adverse drug reactions.The development and marketing of dupilumab has provided a new therapeutic option for type 2 inflammatory skin diseases,but dupliumab is often used off-label for other type 2 inflammatory skin diseases clinically.In this review,the application of dupliumab in type 2 inflammatory skin diseases in recent years was reviewed,with a view to providing new ideas for the treatment of this type of patients and looking forward to the clinical application of biologics.
type 2 inflammatory skin diseasedupilumabtargeted biologicsover-indication
NETL
NSTL
万方数据
